^
BIOMARKER:

KRAS mutation

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related biomarkers:
KRAS mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
B
Onco Targets Ther - 6 days - (New C3)
KRAS mutation
Non Small Cell Lung Cancer
durvalumab + CP-675206
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
KRAS mutation
Colorectal Cancer
bevacizumab + PCM-075
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS mutation
Colorectal Cancer
cetuximab
Resistant
:
B
KRAS mutation
Colorectal Cancer
trifluridine / tipiracil
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
B
KRAS mutation
Acute Myelogenous Leukemia
gilteritinib
Resistant
:
B
KRAS mutation
Non Small Cell Lung Cancer
abemaciclib
Sensitive
:
B
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
selumetinib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
nivolumab
Sensitive
:
B
KRAS mutation
Colorectal Cancer
regorafenib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
erlotinib
Resistant
:
B
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive
:
B
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive
:
B
KRAS mutation
Ovarian Cancer
binimetinib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
pembrolizumab + abemaciclib
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
bevacizumab + PCM-075
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
trametinib
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
afatinib + selumetinib
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
bevacizumab
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
eFT226
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
VS-6766
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
GSK3070785
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
anlotinib
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
sunitinib
Sensitive
:
C2
KRAS mutation
Ovarian Cancer
VS-6766 + VS-6063
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
bevacizumab + cetuximab
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
palbociclib + binimetinib
Sensitive
:
C2
KRAS mutation
Melanoma
trametinib
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
cetuximab + selumetinib
Sensitive
:
C2
KRAS mutation
Pancreatic Cancer
avelumab
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
TVB-2640
Sensitive
:
C2
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
binimetinib
Sensitive
:
C2